Sarah Premji, MD, of Sarah Cannon Research Institute discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
|Videos|August 9, 2016
The Convergence of Targeted Therapies and Immuno-Oncology in Sarcoma
Author(s)George D. Demetri, MD
George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses the relevance of sarcoma in the converging worlds of targeted therapies and immuno-oncology.
Advertisement
Advertisement
Related to this article
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Behind the FDA Approval of Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
PRV111 Shows Strong Responses in Early Oral Cancer
5